The Safety and Effectiveness of a Type of Interleukin-2 Plus Zidovudine Plus Thymosin in HIV-Positive Patients With and Without Symptoms of Infection

Inclusion Criteria Concurrent Medication: Allowed: Prophylactic pentamidine for Pneumocystis carinii. Patients must have: HIV seropositivity. CD4 count > 50 and < 200 cells/mm3. No active opportunistic infections. Exclusion Criteria Co-existing Condition: Patients with the following symptoms or conditions are excluded: Concurrent neoplasms other than basal cell carcinoma of the skin, in situ carcinoma of the cervix, or Kaposi's sarcoma. Significant cardiac disease or CNS lesions or other neurologic abnormalities. Score of > 0.5 on ACTG AIDS Dementia Complex staging. Major organ allograft. Intolerance to AZT at 500 mg/day. Concurrent Medication: Excluded: Antihypertensive medication other than diuretics. Chemotherapy, hormonal therapy, or other immunotherapy. Other investigational drugs, agents, or devices. Beta-blockers. Non-topical steroids. Concurrent Treatment: Excluded: Radiation therapy. Prior Medication: Excluded: Known anti-HIV medication (other than AZT) or known immunomodulators (e.g., systemic steroids, interferons, interleukins) or other chemotherapy within 30 days prior to study entry. Prior Treatment: Excluded: Transfusion within 4 weeks prior to study entry. Radiation within 30 days prior to study entry. Active substance abuse.